key: cord-0748325-y9b0o98h
authors: Hollerbach, Anne; Müller‐Calleja, Nadine; Pedrosa, Denise; Canisius, Antje; Sprinzl, Martin F.; Falter, Tanja; Rossmann, Heidi; Bodenstein, Marc; Werner, Christian; Sagoschen, Ingo; Münzel, Thomas; Schreiner, Oliver; Sivanathan, Visvakanth; Reuter, Michael; Niermann, Johannes; Galle, Peter R.; Teyton, Luc; Ruf, Wolfram; Lackner, Karl J.
title: Pathogenic lipid‐binding antiphospholipid antibodies are associated with severity of COVID‐19
date: 2021-07-22
journal: J Thromb Haemost
DOI: 10.1111/jth.15455
sha: 1c91c7a5fb45fea2b9bdc52c621db4d1453d9266
doc_id: 748325
cord_uid: y9b0o98h

BACKGROUND: Coronavirus disease 19 (COVID‐19)–associated coagulopathy is a hallmark of disease severity and poor prognosis. The key manifestations of this prothrombotic syndrome—microvascular thrombosis, stroke, and venous and pulmonary clots—are also observed in severe and catastrophic antiphospholipid syndrome. Antiphospholipid antibodies (aPL) are detectable in COVID‐19 patients, but their association with the clinical course of COVID‐19 remains unproven. OBJECTIVES: To analyze the presence and relevance of lipid‐binding aPL in hospitalized COVID‐19 patients. METHODS: Two cohorts of 53 and 121 patients from a single center hospitalized for PCR‐proven severe acute respiratory syndrome–coronavirus 2 infection were analyzed for the presence of aPL and clinical severity of COVID‐19. RESULTS: We here demonstrate that lipid‐binding aPL are common in COVID‐19. COVID‐19 patients with lipid‐binding aPL have higher median concentrations of C‐reactive protein and D‐dimer, and are more likely to have a critical clinical course and fatal outcome. Lipid‐binding aPL isolated from COVID‐19 patients target the recently described cell surface complex of lysobisphosphatidic acid (LBPA) with the protein C receptor (EPCR) to induce prothrombotic and inflammatory responses in monocytes and endothelial cells. We show that B1a cells producing lipid‐reactive aPL of the IgG isotype circulate in the blood of COVID‐19 patients. In vivo, COVID‐19 aPL accelerate thrombus formation in an experimental mouse model dependent on the recently delineated signaling pathway involving EPCR‐LBPA. CONCLUSIONS: COVID‐19 patients rapidly expand B1a cells secreting pathogenic lipid‐binding aPL with broad thrombotic and inflammatory effects. The association with markers of inflammation and coagulation, clinical severity, and mortality suggests a causal role of aPL in COVID‐19–associated coagulopathy.

Coronavirus disease 19 (COVID-19)-associated coagulopathy (CAC) has been amply described as a major complication related to disease severity and poor outcome. [1] [2] [3] Besides venous and arterial thrombotic events, lungs of COVID-19 patients show prominent endothelial injury and widespread thrombosis and capillary microthrombi. 4 Several potential mechanisms underlying CAC have been proposed 5, 6 including antiphospholipid antibodies (aPL), which have been detected in some COVID-19 patients. [7] [8] [9] While aPL are causally involved in the pathogenesis of antiphospholipid syndrome (APS), an autoimmune disease characterized by thromboembolic events and pregnancy complications, 10 their functional role in CAC is poorly understood and so far no association with clinical events or death has been described. It should be noted that aPL are also frequently observed transiently during the course of several infectious diseases, 11 but these infection-associated aPL have not been considered pathogenic previously. 10, 12 Catastrophic APS (CAPS) is a rare acute, life-threatening form of APS, characterized by widespread vascular occlusions leading to organ failure. Pulmonary capillaritis, small vessel thrombosis, and diffuse alveolar hemorrhage leading to adult respiratory distress syndrome are major signs of lung involvement in CAPS 13 and overlap with the pulmonary pathologies observed in severe COVID-19. 4, 6 Importantly, infections are considered a major precipitating factor of CAPS. 13 Although various aPL reactivities have been observed at different frequency in COVID-19 patients and linked to thrombosis, [7] [8] [9] We have shown that lipid-binding aPL of the IgG isotype are pathogenic in vivo and elucidated the underlying signal transduction. [14] [15] [16] [17] The cellular target for aPL is the endosomal phospholipid • Antiphospholipid antibodies (aPL) were determined in two cohorts of COVID-19 patients.

• Lipid-binding aPL produced by B1a cells were associated with severity and mortality of COVID-19.

• aPL induce prothrombotic and inflammatory effects by targeting the complex of endothelial protein C receptor and lysobisphosphatidic acid.

aPL were determined in all COVID-19 patients by Quanta Flash automated chemiluminescent immunoassays (Instrumentation Laboratory) for anticardiolipin IgG and IgM, and anti-β2-glycoprotein I (β2GPI) IgG and IgM using the cutoffs determined in a large German cohort. 18 Antibodies against the complex of phosphatidylserine and prothrombin (anti-PS/PT) of the IgG and IgM isotype were determined by ELISA (Instrumentation Laboratory) using the cutoff recommended by the supplier (30 CU). Additionally, anticardiolipin and anti-LBPA IgG were determined in a homemade ELISA format that does not contain protein cofactors, as described previously. 19 Tween-20 in DPBS followed by another washing step. 10 µL serum diluted 1:10 in DPBS were added and incubated 1 h at room temperature (RT). After washing, bound human IgG was detected with horseradish peroxidase-conjugated goat anti-human IgG (#A0293-1ML, Sigma) diluted 1:10,000 (1 h, RT) followed by a final washing step.

TMB substrate (#T0440-100ML, Sigma) was incubated 5 min in the dark and the reaction was stopped by adding 2N H 2 SO 4 . Optical density (OD) was measured at 450 nm (reference 620 nm) using an Ao Microplate Reader (Azure Biosystems, Inc.). The anticardiolipin assay was calibrated using the human monoclonal lipid-binding aPL HL5B and results are reported as arbitrary units (AU). The cutoff for positivity was determined at 26 AU, which represents the mean of 27 randomly picked controls from the local population (participants of the Gutenberg Health Study) 18 plus 3 standard deviations.

Due to the limited availability of serum we used, preferentially, immunoglobulins purified by ammonium sulfate precipitation rather than IgG purified by protein G affinity binding. Immunoglobulins were precipitated in 40% (v/v) saturated ammonium sulfate (#3746.3, Roth) solution for 3 h on ice. The precipitate was collected by centrifugation and the immunoglobulin fraction was resuspended in PBS and desalted using PD MiniTrap G25 columns (#28918007, GE Healthcare) following the manufacturer's instructions. To ascertain that cellular activation was mediated by the IgG-fraction, we isolated IgG from 3 patients with sufficient surplus serum and positive for lipid-binding aPL by protein G affinity adsorption as previously described and determined induction of TNF mRNA in monocytes. 14 

The human monocytic cell line MonoMac 1 (MM1) was exposed to immunoglobulin fractions and procoagulant activity was determined as previously described. 14 Based on a standard curve of recombinant tissue factor (TF; hemosIL RecombiPlasTin 2G, #0020003051, Instrumentation Laboratory, Munich, Germany) clotting times were converted into procoagulant activity (PCA) units. Table S2 in supporting information. Table S3 in supporting information.

aPL-producing B cells were detected in ethylenediaminetetraacetic acid (EDTA) blood by staining with fluorescently labelled phospholipid vesicles as previously described. 14 Fc-receptors were blocked prior to the antibody staining to avoid unspecific labelling of the cells (FcR blocking reagent, #130-059-901, Miltenyi Biotec). Cell surface staining was performed using labeled antibodies listed in Table S4 in supporting information. Soluble EPCR (sEPCR) and sEPCR loaded with LBPA was prepared as described. 14,21 EDTA blood was stained with phospholipid vesicles or fluorescently labeled β2GPI and the respective antibodies as indicated for 30 min at 4°C in the dark. After washing with cold PBS/1% BSA cells were incubated with Red blood cell lysis buffer (#420301, BioLegend) for 10 min at RT. Subsequently, cells were pelleted and resuspended in PBS. Fluorescently labeled cells were detected using a FACS Lyric flow cytometer (BD). FlowJo 7.2 software was used for data analysis.

aPL-induced thrombus formation in vivo was determined as previously described. 14, 17 Immunoglobulins isolated from six critical Covid-19 patients or healthy controls (10 µg) were injected via jugular catheter into wild-type mice 1 h prior to flow reduction in the inferior vena cava (IVC) induced by ligation. Antibodies directed against the endothelial protein C receptor (αEPCR) were injected through the catheter 15 min before immunoglobulins. Rhodamine Blabeled (#R1755, Sigma) platelets and 100 µL of 50 mg/mL Acridine Orange (#A6014, Sigma) to label leukocytes were used to visualize the evolving thrombi. Thrombus formation was imaged by highspeed fluorescence video microscopy using a high-speed wide-field Olympus BX51WI fluorescence microscope.

Continuous data are shown as means ± standard deviation or median and interquartile range (IQR) as appropriate. To compare two 

We hypothesized that lipid-binding aPL occur during COVID-19 as has been described in other viral diseases. Table 1 (Table S1 ). As expected, critical patients showed a marked elevation of markers of inflammation (C-reactive protein) and coagulopathy (D-dimer). Concentrations of ferritin and white blood cell counts also tended to be higher in critical patients, but there was a major overlap in the range of measurements between patient groups.

In the commercial clinical routine assays, anticardiolipin IgG titers were significantly higher in critical patients, but the majority of patients in both groups had titers within the reference range. Only a few patients (one non-critical and six critical) had titers above the diagnostic cutoff (Table 1) . One critical COVID-19 patient tested positive for anti-β2GPI IgG and none for aPL of the IgM isotype. Four patients (two critical and two non-critical) had antibodies directed against the complex of anti-PS/PT of the IgM isotype. No anti-PS/ PT of the IgG isotype were detected (Table 1) . Lupus anticoagulant activity, which is caused by autoantibody interference with different steps in the clotting cascade, 22 could not be determined due to insufficient amounts of surplus citrate plasma.

Because commercial assays for anticardiolipin reactivity contain β2GPI and are designed to be less sensitive for lipid-binding aPL, 12 we analyzed the reactivity of patient IgG on ELISA plates coated with cardiolipin alone calibrated with a human monoclonal lipidbinding aPL (HL5B). Critical patients had significantly higher titers than non-critical patients in this assay, which detects lipid-binding aPL of the IgG isotype. They were also more likely to test positive, that is, more than three standard deviations higher titers than the mean of the control group. In the assay format measuring specifically lipid-reactive aPL, 29 of 53 patients were positive ( Table 2) We have recently identified LBPA presented by EPCR on the cell surface as an antigenic target for lipid-binding aPL which bind efficiently to cardiolipin and other negatively charged phospholipids in the ELISA format. 14 Therefore, we analyzed serum samples of both cohorts for binding to LBPA in an ELISA. Correlation between anticardiolipin and anti-LBPA results expressed as optical density was very good (r 2 = 0.8654; Figure S1 in supporting information).

These data suggested EPCR-LBPA as the target for aPL developing in COVID-19 patients.

Lipid-binding aPL in mice are secreted by a circulating population of B1a cells. This population expands dependent on TLR7 signaling and secretion of IFNα by dendritic cells. 14 We therefore analyzed peripheral blood B cells in 10 patients of the cohort described above.

We identified a distinct circulating B cell population reactive with fluorescently labeled phospholipid vesicles; these B cells were not detectable in healthy controls and represented approximately 25% of circulating CD19 + lymphocytes ( Figure 1A,B) . Notably, COVID-19 patients had no B cells that were reactive with β2GPI or prothrombin ( Figure 1B) , while B cells reactive with β2GPI can be readily detected in patients with APS ( Figure S2 in supporting information). This is in line with the low prevalence of aPL directed against β2GPI

in the present study and other series of COVID-19 patients. [7] [8] [9] Phospholipid-reactive B cells expressed CD20, CD27, and CD43 and were IgG positive ( Figure 1D,E) , but lacked CD38 expression. This profile is typical for B1a cells, although this subtype is not as well defined by surface markers in humans as it is in mice. 23 Recent studies have demonstrated an expansion of plasmablasts in COVID-19 patients during acute infection, which is likely related to the SARS-CoV-2-specific antibody response. 24 This response is apparently very rapid, because it can build on existing germline sequences in the population that require few somatic mutations to gain specificity for SARS-CoV-2. 25 Plasmablasts related to this response express CD38 but not CD20, demonstrating that they are distinctly different from the phospholipid-binding B cell population described here.

Lipid-reactive aPL only bind to sEPCR after exchange of the structurally bound phosphatidylcholine with LBPA. 14 Figure 2C ). These data further indicated that no functionally relevant anti-β2GPI reactivity was present in these patient sera.

Since activation of the endothelium has been described in COVID-19 pathology, we extended our in vitro analysis to this cell type. Immunoglobulin from COVID-19 patients also rapidly induced TNF and F3 in HUVEC ( Figure 2D ). As observed in monocytic cells, this activation was also dependent on complement, EPCR, and endo- Abbreviations: CRP, C-reactive protein; n.s., not significant; SD, standard deviation; WBC, white blood cell.

Thrombus growth was comparable to previously observed effects of lipid-binding aPL. 14, 16, 17 We applied a specific inhibitory antibody to EPCR--LBPA (αEPCR 1682) and a binding, but non-inhibitory control antibody (αEPCR 1650) to define the underlying mechanism of COVID-19 immunoglobulin-induced thrombosis. 14 Note that both antibodies to EPCR have no effect on EPCR-dependent protein A limitation of our study is the single-center, retrospective, observational design, which did not permit inclusion of all COVID-19

patients. In particular, younger patients with mild to moderate disease were discharged early without availability of serum for aPL determination. This is reflected in the high proportion of critical patients in the first cohort. We therefore analyzed a second cohort with a focus on available aPL results for disease severity and mortality.

We have previously shown in mice that lipid-binding aPL signifi- Genetic susceptibility to severe COVID-19 has furthermore been linked to TF as well as coagulation and complement regulatory proteins. 36 Together with the robust activation of inflammatory and have no conflict of interest to report.

Müller-Calleja collected data, performed experiments, and wrote the manuscript

Pedrosa performed the in vivo mouse experiments

Canisius performed experiments; T. Falter and H. Rossmann collected laboratory data

Galle were responsible for patient care and collected clinical data

Teyton provided critical reagents

Lackner conceived and designed the study, and wrote and edited the manuscript

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Clinical characteristics of coronavirus disease 2019 in China

Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia

Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19

Emerging evidence of a COVID-19 thrombotic syndrome has treatment implications

Proposal of the definition for COVID-19-associated coagulopathy

Antiphospholipid antibodies in patients with COVID-19: a relevant observation?

Prothrombotic autoantibodies in serum from patients hospitalized with COVID-19

Antiphospholipid antibodies in COVID-19: a meta-analysis and systematic review

Antiphospholipid syndrome

Antiphospholipid antibodies, antiphospholipid syndrome and infections

Subcommittee on Lupus Anticoagulant/ Antiphospholipid Antibodies. Laboratory criteria for antiphospholipid syndrome: communication from the SSC of the ISTH

Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of 500 patients from the international CAPS registry

Lipid presentation by the protein C receptor links coagulation with autoimmunity

Antiphospholipid-antibodies induce translocation of TLR7 and TLR8 to the endosome in human monocytes and plasmacytoid dendritic cells

Tissue factor pathway inhibitor primes monocytes for antiphospholipid antibody-induced thrombosis

Cofactor independent human antiphospholipid antibodies induce venous thrombosis in mice

Distribution of antiphospholipid antibodies in a large population-based German cohort

Cofactor-independent antiphospholipid antibodies activate the NLRP3-inflammasome via endosomal NADPH-oxidase: implications for the antiphospholipid syndrome

Endosomal NADPHoxidase is critical for induction of the tissue factor gene in monocytes and endothelial cells. Lessons from the antiphospholipid syndrome

The endothelial protein C receptor supports tissue factor ternary coagulation initiation complex signaling through protease-activated receptors

Anti-β2-glycoprotein I and anti-prothrombin antibodies cause lupus anticoagulant through different mechanisms of action

Distinctions among circulating antibody-secreting cell populations, including B-1 cells, in human adult peripheral blood

Longitudinal multi-omics analyses identify responses of megakaryocytes, erythroid Cells, and plasmablasts as hallmarks of severe COVID-19

Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients

Complement C5 but not C3 is expendable for tissue factor activation by cofactor-independent antiphospholipid antibodies

Antiphospholipid antibody induced cellular responses depend on epitope specificity -implications for treatment of APS

Viral hepatitis and anti-phospholipid antibodies positivity: a systematic review and meta-analysis

Cytomegalovirus-associated venous and arterial thrombotic disease

Hydroxychloroquine inhibits proinflammatory signalling pathways by targeting endosomal NADPH oxidase

Immunothrombotic dysregulation in COVID-19 pneumonia is associated with respiratory failure and coagulopathy

Complement and tissue factor-enriched neutrophil extracellular traps are key drivers in COVID-19 immunothrombosis

Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys

Patients with COVID-19 have elevated levels of circulating extracellular vesicle tissue factor activity that is associated with severity and mortality

Dissemination of extreme levels of extracellular vesicles: tissue factor activity in patients with severe COVID-19

Immune complement and coagulation dysfunction in adverse outcomes of SARS-CoV-2 infection

SARS-CoV-2 drives JAK1/2-dependent local complement hyperactivation

Complement activity and complement regulatory gene mutations are associated with thrombosis in APS and CAPS

Tissue factor at the crossroad of coagulation and cell signaling

Multiple roles of the coagulation protease cascade during virus infection

Myeloid cell-synthesized coagulation factor X dampens antitumor immunity